Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

Lassalle A.; Thomare P.; Fronteau C.; Mahe B.; Jube C.; Blin N.; Voldoire M.; Dubruille V.; Tessoulin B.; Touzeau C.; Chauvin C.; Loirat M.; Lok A.; Bourcier J.; Lestang E.; Mocquet R.; Barbarot V.; Moreau P.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

【24h】

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

机译：硼替佐米在多发性骨髓瘤中的家庭管理具有成本效益，并且比医院管理更受患者青睐：一项前瞻性单中心研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Subcutaneous (s.c.) administration of bortezomib is the most widely used route of administration for the treatment of patients with multiple myeloma. No study has as yet prospectively evaluated home versus hospital administration of s.c. bortezomib with respect to patient preference and cost.

机译：背景：硼替佐米皮下注射是治疗多发性骨髓瘤患者最广泛使用的途径。尚无前瞻性评估s.c.家庭与医院管理的研究。硼替佐米在患者喜好和费用方面。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2016年第2期|共6页
作者
Lassalle A.; Thomare P.; Fronteau C.; Mahe B.; Jube C.; Blin N.; Voldoire M.; Dubruille V.; Tessoulin B.; Touzeau C.; Chauvin C.; Loirat M.; Lok A.; Bourcier J.; Lestang E.; Mocquet R.; Barbarot V.; Moreau P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
multiple myeloma; subcutaneous bortezomib; cost analysis; quality of life;

机译：多发性骨髓瘤;皮下硼替佐米;成本分析;生活质量;

相似文献

外文文献
中文文献
专利

1. 对可切除的中/低位直肠癌是/否进行术前放化疗的全直肠系膜切除术研究:一项前瞻性、单中心、随机试验的长期分析 [J] . Fulong Wang, Xiaojun Wu, Peirong Ding, 癌症（英文版） . 2019,第005期
2. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study [J] . Lassalle A., Thomare P., Fronteau C., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第2期

机译：硼替佐米在多发性骨髓瘤中的家庭管理具有成本效益，并且比医院管理更受患者青睐：一项前瞻性单中心研究的结果
3. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. [J] . Moreau P, Pylypenko H, Grosicki S, The lancet oncology . 2011,第5期

机译：硼替佐米皮下注射或静脉内注射治疗复发性多发性骨髓瘤：一项随机，3期，非自卑性研究。
4. Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT) [J] . Yamga Eric, Leblanc Richard, Boudreault Jean-Samuel Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：加拿大回顾性的多中心研究比较硼佐米，环磷酰胺和地塞米松（Cybord）的组合与硼替佐米，沙利度胺和地塞米松（VTD）与硼喹啉和地塞米松（VD）进行新诊断的多发性脑膜患者，其中有资格获得自体造血干细胞移植（HCT）
5. Using Simulation to Improve Patient Access and Reduce Cost: case study in a Veterans Administration hospital [C] . Tom Rust, Khalid Saeed, Sharon Johnson Annual Conference and Expo of the Institute of Industrial Engineers . 2014

机译：利用模拟改善患者访问和降低成本：退伍军人管理医院的案例研究
6. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
7. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study [O] . Masahiro Kondo, Yuji Hotta, Karen Yamauchi, 2020

机译：Bortezomib管理是与多发性骨髓瘤患者肿瘤裂解综合征的发展相关的危险因素：回顾性研究
8. Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? [O] . Gozzetti, Alessandro, Candi, Veronica, Zuanelli Brambilla, Corrado, 2016

机译：在对皮下硼替佐米给药无反应后静脉注射（IV）硼替佐米可引起多发性骨髓瘤患者的短暂反应：是否有任何患者对静脉注射硼替佐米更敏感？
9. Community Hospitals Serving VA (Veterans Administration) Sponsored Patients: A Manual for Sharing and Contractual Arrangements between the Veterans Administration and Community Hospitals [R] . 1986

机译：社区医院服务Va（退伍军人管理局）赞助患者：退伍军人管理局和社区医院之间的分享和合同安排手册

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

摘要

著录项

相似文献

相关主题

期刊订阅